8-K - NovoCure Limited | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

NovoCure Limited announced positive topline results from the Phase 2 PANOVA-4 trial on March 26, 2026, meeting its primary endpoint with a 74.4% disease control rate (DCR) for Tumor Treating Fields therapy combined with atezolizumab, gemcitabine, and nab-paclitaxel in first-line metastatic pancreatic ductal adenocarcinoma, versus 48% in historical control (p<0.001). This supports advancing TTFields therapy for metastatic pancreatic cancer.

Key Takeaways

1PANOVA-4 trial met primary endpoint: DCR 74.4% (N=78) vs 48% historical control (N=431 from Phase 3 MPACT), difference 26.4%, 1-sided p<0.001

2Objective response rate (ORR) 34.6% (95% CI: 24.2%-46.2%)

3Median overall survival (OS) 9.7 months (95% CI: 7.9-12.7 months)

4Median TTFields therapy duration 25.6 weeks; median systemic therapy 6 cycles

5TTFields therapy well-tolerated, consistent with prior studies

6Plans to present additional PANOVA-4 results at future scientific forum

Current Report Details

Event Type

Regulation Fd

Exhibits Only

Disclosure

Voluntary

Variant

8-K

Items Reported

7.01

Regulation FD Disclosure. On March 26, 2026, the Company issued a press release announcing positive results from the Phase 2 PANOVA-4 trial of Tumor Treating Fi

Regulation Fd

9.01

Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 99.1 Press Release of NovoCure Limited, dated March 26, 2026 104 Cover Page Interactive D

Exhibits Only

Source Document

Exhibits (2)

8-K

99.1

EX-99.1